Get started
Author

Andrés Lamsfus‐Calle

Observed names: Andres Lamsfus-Calle, Andrés Lamsfus-Calle
ORCID: 0000-0002-4464-0152
Observed ORCID: 0000-0002-4464-0152
OpenAlex ID: A5063253785
Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin
2020 · Andrés Lamsfus-Calle, Alberto Daniel-Moreno, et al. · Scientific Reports · 62
PDF
Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors
2018 · Justin S. Antony, Ngadhnjim Latifi, et al. · Molecular and Cellular Pediatrics · 55
PDF
CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation
2019 · Alberto Daniel-Moreno, Andrés Lamsfus-Calle, et al. · Bone Marrow Transplantation · 41
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
2019 · Andrés Lamsfus-Calle, Alberto Daniel-Moreno, et al. · Blood Reviews · 29
CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies
2019 · Guillermo Ureña-Bailén, Andrés Lamsfus-Calle, et al. · Briefings in Functional Genomics · 23
CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases
2018 · Justin S. Antony, A.K.M. Ashiqul Haque, et al. · Advances in Cell and Gene Therapy · 20
PDF
Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors
2025 · Ane Arrasate, Carlos Lopez-Robles, et al. · International Journal of Molecular Sciences · 14
PDF
Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors
2024 · Ane Arrasate, Igone Bravo, et al. · Biomedicines · 14
Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
2022 · Yujuan Hou, Guillermo Ureña-Bailén, et al. · Genes · 14
PDF
A Mutation-Agnostic Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy
2021 · Justin S. Antony, Alberto Daniel-Moreno, et al. · The CRISPR Journal · 12
Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies
2023 · Guillermo Ureña-Bailén, Milena Block, et al. · The CRISPR Journal · 11
Abolishing Retro-Transduction of Producer Cells in Lentiviral Vector Manufacturing
2024 · Soledad Banos-Mateos, Carlos Lopez-Robles, et al. · Viruses · 10
PDF
Universal Gene Correction Approaches for β-hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates
2021 · Andrés Lamsfus-Calle, Alberto Daniel-Moreno, et al. · The CRISPR Journal · 9
Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathy
2021 · Héctor O. Rodríguez‐Angulo, Andrés Lamsfus‐Calle, et al. · Annals of the New York Academy of Sciences · 4
PDF
Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies
2020 · Alberto Daniel-Moreno, Andrés Lamsfus-Calle, et al. · Blood Cells Molecules and Diseases · 3
Generation of a heterozygous and a homozygous CSF1R knockout line from iPSC using CRISPR/Cas9
2023 · Anne S. Schmitz, Milena Korneck, et al. · Stem Cell Research · 1
From Platform Development to Scale-Up: Stable Producer Cell Line-Based Lentiviral Vector Manufacturing
2026 · Ane Arrasate, Igone Bravo, et al. · Pharmaceutics
CRISPR Medicine: Advance, Progress and Challenges
2021 · Guillermo Ureña-Bailén, Justin S. Antony, et al. · CRC Press eBooks
Works count: 18
Citation count: 322
H-index: 11
I10-index: 12
Year
Topic
Type